Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors

Vivera Pharmaceuticals' Chief Medical Officer Dr. Stephen J. McColgan Appointed Clinical Instructor At University of California, Riverside, School of Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 09:10am EDT

Newport Beach, California--(Newsfile Corp. - August 14, 2019) - Vivera Pharmaceuticals, Inc., a pharmaceutical company focused on non-addictive pain management is pleased to announce that its Chief Medical Officer, Dr. McColgan, has been appointed as Clinical Instructor at the University of California, Riverside (UCR), School of Medicine. The UCR School of Medicine is known for successfully developing new methods and frontiers in medical teaching. Dr. McColgan joined the faculty effective August 1, 2019.

"It is both an honor and a privilege to receive this appointment," said Dr. McColgan. "Coming from a private practice background rather than a purely academic one, it's an exciting opportunity for me to be able to offer a different perspective to impact new medical students."

Dr. McColgan was one of the first surgeons to perform laparoscopic cholecystectomy, laparoscopic nissen fundoplication, and laparoscopic gastric bypass in the Southern California area. He was Chairman of the Department of Surgery for Bellflower Medical Center for more than 10 years and was a founding member of Endodynamix, Inc., a manufacturer of surgical instruments.

According to rankings published by the Center for World University Rankings, a consultancy based in the United Arab Emirates, UCR is among the top 1% of universities in the world. In the recently released 2019-2020 list, UCR came in at 204 out of 18,000 total universities worldwide, moving up in rankings from last year. Institutions are evaluated on the quality of teaching, alumni employment, quality of faculty, research output, high-quality publications, influence and citations.

"UCR is recruiting the top, best and brightest in the world," said Greg Cervantes, Director of Government Affairs for Vivera. "I believe adding Dr. McColgan to their faculty is a tremendous benefit to the field of medicine and research. I congratulate Dr. McColgan and view him as one of the nation's top physicians."

"Dr. McColgan's appointment speaks volumes to his accomplishments and reputation," said Paul Edalat, Chairman and Founder of Vivera. "At Vivera, we've always viewed him as a distinguished member amongst his peers so it's great to see that UCR recognizes that as well."

Dr. McColgan was born in Boston, Massachusetts. He is a graduate of Boston University and the Boston University School of Medicine. He completed his general surgery training at the University of California, Irvine, where he served as Chief Resident. In addition, he earned an MBA from the University of California, Irvine.

Figure 1: Dr. Stephen J. McColgan

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6166/46933_5acf6485b486abb3_001.jpg


To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6166/46933_5acf6485b486abb3_001full.jpg

About Vivera Pharmaceuticals, Inc.

Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical company focused on opioid deterrence and cessation and non-addictive solutions for pain management.

In addition to its pharmaceutical and medical device products, the company has global exclusivity to license the patented and patent-pending TABMELT™ sublingual drug-delivery system for the pharmaceutical use of cannabinoid compounds.

Vivera Pharmaceuticals is seeking to conduct case studies and clinical trials on CBD in the TABMELT™ drug delivery format with the goal of gaining FDA approval for its products.

The company is vertically integrated with patented technology, manufacturing capabilities and distribution for its products.

For more information, visit https://viverapharmaceuticals.com.

Investor Relations Inquiries:
thinkHERO
Patrick Piette, CFA for Vivera Pharmaceuticals, Inc.
416-526-9911
investorrelations@viverapharma.com

Press Inquiries:
thinkHERO
Karin Elz, for Vivera Pharmaceuticals, Inc.
416-992-9848
press@viverapharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/46933


© Newsfilecorp 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news "Companies"
10:06aELBIT : Portuguese MoD Selects Elbit Systems to Provide a Complete EW Suite for the Portuguese Air Forces' New KC-390 Aircraft
PU
10:06aSOLAREDGE TECHNOLOGIES : Announces Death of Co-Chairman and Founder, Guy Sella
BU
10:03aBASEBALL : Pacific League standings (Aug. 25)
AQ
09:15aLatest Round of Stock Volatility Adds to August Turbulence
DJ
09:02aTrump dangles 'very big' trade deal in front of Brexit Britain
RE
08:56aHONG KONG EXCHANGES AND CLEARING : Notification Letter and Request Form to Registered Shareholders
PU
08:56aHONG KONG EXCHANGES AND CLEARING : Notification Letter and Request Form to Non-registered Shareholders
PU
08:51aSS LAZIO : Serie A TIM | Sampdoria-Lazio, squad named
PU
08:36aBMW : Motorsport News - Issue 30/2019.
PU
08:31aHONG KONG EXCHANGES AND CLEARING : Announcement of unaudited interim results for the six months ended 30 june 2019
PU
Latest news "Companies"
Advertisement